The High Cost Of Hope: When The Parallel Interests Of Pharma And Families Collide
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.
Patient Advocacy Groups Take In Millions From Drugmakers. Is There A Payback?
Kaiser Health News launches “Pre$cription for Power,” a groundbreaking database to expose Big Pharma’s ties to patient groups.
Whichever Way ‘Repeal and Replace’ Blows, Pharma Is Due For Windfall
A little-noticed provision in President Donald Trump’s executive order on drug prices may offer a clue to why Big Pharma hasn’t opposed a bill that could bleed their balance sheets of millions of patients.
Exclusive: White House Task Force Echoes Pharma Proposals
Documents examined by Kaiser Health News shed light on the workings of the Trump administration’s “Drug Pricing and Innovation Working Group.”
Tweet Revenge: Twitter Erupts As Diabetes Forum Tries To Lock Down Photo Sharing
This year’s American Diabetes Association scientific meeting comes with a hefty price — a policy of no photography and limits on social media. That did not go over well on Twitter.
Daylight On Diabetes Drugs: Nevada Bill Would Track Insulin Makers’ Profits
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
Nonprofit Linked To PhRMA Rolls Out Campaign To Block Drug Imports
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
Senators Demand Answers About Possible Probe Of HHS Secretary Price
Democratic senators want the Justice Department to reveal what it knows about ProPublica’s recent report that HHS Secretary Tom Price’s stock trades were under investigation by former U.S. Attorney Preet Bharara before the Trump administration fired him.
Report: Fired U.S. Attorney Was Probing Tom Price’s Stock Trades
The HHS Secretary bought stock in companies that stood to benefit from legislation he voted for and sponsored as a Georgia congressman.
Patient Advocacy Groups Rake In Donations From Pharma
A new study shows that 83 percent of the largest patient advocacy groups take contributions from drug, medical device or biotech firms.